Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.
about
miR-17-92 expression in differentiated T cells - implications for cancer immunotherapyToll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor modelsImmunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?Integration of epidemiology, immunobiology, and translational research for brain tumorsExpression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenograftsEffective immunotherapy against murine gliomas using type 1 polarizing dendritic cells--significant roles of CXCL10.Chemokines as Cancer Vaccine Adjuvants.Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic virusesPoly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent mannersRole of type 1 IFNs in antiglioma immunosurveillance--using mouse studies to guide examination of novel prognostic markers in humans.Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells.Cytotoxic T lymphocyte trafficking and survival in an augmented fibrin matrix carrier.Combination of an agonistic anti-CD40 monoclonal antibody and the COX-2 inhibitor celecoxib induces anti-glioma effects by promotion of type-1 immunity in myeloid cells and T-cells.Neem leaf glycoprotein activates CD8(+) T cells to promote therapeutic anti-tumor immunity inhibiting the growth of mouse sarcomaInduction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcelluloA therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment.In vivo intracellular oxygen dynamics in murine brain glioma and immunotherapeutic response of cytotoxic T cells observed by fluorine-19 magnetic resonance imagingSystemic delivery of neutralizing antibody targeting CCL2 for glioma therapy.Synergy between CD8 T cells and Th1 or Th2 polarised CD4 T cells for adoptive immunotherapy of brain tumoursInduction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC.Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment.Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity.Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomasImmune cell recruitment and cell-based system for cancer therapy.Adoptive transfer of Tc1 or Tc17 cells elicits antitumor immunity against established melanoma through distinct mechanismsCCR7 regulates B16 murine melanoma cell tumorigenesis in skinStat6 signaling suppresses VLA-4 expression by CD8+ T cells and limits their ability to infiltrate tumor lesions in vivo.Anti-tumor activity and trafficking of self, tumor-specific T cells against tumors located in the brainExtranodal induction of therapeutic immunity in the tumor microenvironment after intratumoral delivery of Tbet gene-modified dendritic cellsImmunotherapeutic approaches for gliomaCharacterization and immunotherapeutic potential of gammadelta T-cells in patients with glioblastoma.IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefitImmune-checkpoint blockade and active immunotherapy for glioma.Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccinesIL-4 suppresses very late antigen-4 expression which is required for therapeutic Th1 T-cell trafficking into tumors.Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.Embracing rejection: Immunologic trends in brain metastasis.Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy.
P2860
Q21245464-A368A2AA-6268-4CA4-A066-539577698772Q21245475-A899888F-39BE-4C49-8DCB-7B5B7044DD6CQ28078539-A0FEBCAF-E43F-48A0-8A75-B0984D6C0CEAQ28397886-2975E770-F2BC-40AB-A42E-C0E609DDA152Q33606096-D1F846CA-7C54-4CB1-A70F-61EE18570E04Q33744525-BC69133A-36A9-4A46-A014-7B0D20D5AA2EQ33792344-33BBADA8-12CA-4F13-B1BF-EF18E92DC855Q33924550-DAEAC291-368A-434F-93F9-4C299411C2D4Q33945653-6749620A-A52B-4027-B98C-AEFAF9B4F101Q33959111-4CAC5573-DFDD-41C7-AD4E-70F214A52C33Q34140756-EB2B07A7-B778-4077-9EB5-C589EF699A00Q34230229-AD938EF7-BF2B-42D4-9A58-FA78ED94265DQ34457611-A5597C00-6D88-4E38-9334-05DA1AB5D679Q34550822-52E873ED-F6CD-46CA-87BB-E8BFE8495BF0Q34666875-DC19C114-187D-4522-8D41-32DE471940DFQ34682173-ECE1EDDC-C3DF-41FA-A45E-349477D44F9FQ34716748-71A93F22-5AAE-459A-8741-6CE42CC44471Q34744555-821CB16E-1D12-4B71-B2B2-2514EE507CD3Q34744875-00AB97DD-A65A-4203-BB57-19D3EFD24828Q34979511-5AB251F0-3372-4413-B6D7-275F383D150FQ35033957-1BD4121E-3548-4E36-9668-5F3A705757BBQ35152154-0D41385A-8434-4A81-B6EF-C5FD6EB92872Q35163556-D3A7CAE3-FF2C-4C58-A3A7-8B22906934C1Q36478070-4749BD43-F9BF-4976-AC48-44FF1CC683EEQ36517706-78D8D5F4-BFCA-4694-8DD6-3C0201E21EF2Q36585688-E4F7CA83-4152-4602-BA60-4930DA8D45DEQ36882300-74E8550E-CDE8-4377-B3CE-8D224C62066FQ37001451-22EF466A-02C3-4B96-9F15-F0AF4772A126Q37037932-DA731C93-8F6D-496E-BEDF-142C929AFF49Q37178505-42F46710-8C7C-4CEB-B89F-ADA509814E34Q37267793-6CAC2119-3F22-455B-91F4-F2CF558984EAQ37344951-4C2F58C8-3434-4D8F-A56F-5344DDFEBACCQ37408970-6F1A9E9D-7840-45A3-BB5E-2AA001B882CAQ37420586-3ADAB691-E1FD-4722-A6A0-E93960426984Q37438563-191BEFCA-E94E-4593-989B-A749D34E978CQ37485130-D54127F4-2876-4A52-8750-6F2F7ADAF663Q37730613-FDCD8AF7-645E-42C7-A92D-0AFBA862D6FCQ37735454-37AF7251-E440-4BCB-A3A8-C8B343B2667BQ38953017-005E10C2-ADCB-4175-BDA2-E7022D19986BQ38988078-C96C9588-47A3-43E1-BE92-FF1BDE382376
P2860
Adoptive transfer of type 1 CTL mediates effective anti-central nervous system tumor response: critical roles of IFN-inducible protein-10.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Adoptive transfer of type 1 CT ...... s of IFN-inducible protein-10.
@en
Adoptive transfer of type 1 CT ...... s of IFN-inducible protein-10.
@nl
type
label
Adoptive transfer of type 1 CT ...... s of IFN-inducible protein-10.
@en
Adoptive transfer of type 1 CT ...... s of IFN-inducible protein-10.
@nl
prefLabel
Adoptive transfer of type 1 CT ...... s of IFN-inducible protein-10.
@en
Adoptive transfer of type 1 CT ...... s of IFN-inducible protein-10.
@nl
P2093
P1433
P1476
Adoptive transfer of type 1 CT ...... s of IFN-inducible protein-10.
@en
P2093
Andrea Gambotto
Fumihiko Nishimura
Hideho Okada
Jill E Dusak
Junichi Eguchi
Xinmei Zhu
P304
P356
10.1158/0008-5472.CAN-05-3825
P407
P577
2006-04-01T00:00:00Z